THE ACTION OP PYRIDINE on DULCITOL HEXANITRATE By
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hereditary Galactokinase Deficiency J
Arch Dis Child: first published as 10.1136/adc.46.248.465 on 1 August 1971. Downloaded from Alrchives of Disease in Childhood, 1971, 46, 465. Hereditary Galactokinase Deficiency J. G. H. COOK, N. A. DON, and TREVOR P. MANN From the Royal Alexandra Hospital for Sick Children, Brighton, Sussex Cook, J. G. H., Don, N. A., and Mann, T. P. (1971). Archives of Disease in Childhood, 46, 465. Hereditary galactokinase deficiency. A baby with galactokinase deficiency, a recessive inborn error of galactose metabolism, is des- cribed. The case is exceptional in that there was no evidence of gypsy blood in the family concerned. The investigation of neonatal hyperbilirubinaemia led to the discovery of galactosuria. As noted by others, the paucity of presenting features makes early diagnosis difficult, and detection by biochemical screening seems desirable. Cataract formation, of early onset, appears to be the only severe persisting complication and may be due to the biosynthesis and accumulation of galactitol in the lens. Ophthalmic surgeons need to be aware of this enzyme defect, because with early diagnosis and dietary treatment these lens changes should be reversible. Galactokinase catalyses the conversion of galac- and galactose diabetes had been made in this tose to galactose-l-phosphate, the first of three patient (Fanconi, 1933). In adulthood he was steps in the pathway by which galactose is converted found to have glycosuria as well as galactosuria, and copyright. to glucose (Fig.). an unexpectedly high level of urinary galactitol was detected. He was of average intelligence, and his handicaps, apart from poor vision, appeared to be (1) Galactose Gackinase Galactose-I-phosphate due to neurofibromatosis. -
In Silico Screening of Sugar Alcohol Compounds to Inhibit Viral Matrix Protein VP40 of Ebola Virus
Molecular Biology Reports (2019) 46:3315–3324 https://doi.org/10.1007/s11033-019-04792-w ORIGINAL ARTICLE In silico screening of sugar alcohol compounds to inhibit viral matrix protein VP40 of Ebola virus Nagasundaram Nagarajan1 · Edward K. Y. Yapp2 · Nguyen Quoc Khanh Le1 · Hui‑Yuan Yeh1 Received: 28 December 2018 / Accepted: 28 March 2019 / Published online: 13 April 2019 © Springer Nature B.V. 2019 Abstract Ebola virus is a virulent pathogen that causes highly lethal hemorrhagic fever in human and non-human species. The rapid growth of this virus infection has made the scenario increasingly complicated to control the disease. Receptor viral matrix protein (VP40) is highly responsible for the replication and budding of progeny virus. The binding of RNA to VP40 could be the crucial factor for the successful lifecycle of the Ebola virus. In this study, we aimed to identify the potential drug that could inhibit VP40. Sugar alcohols were enrich with antiviral properties used to inhibit VP40. Virtual screening analysis was perform for the 48 sugar alcohol compounds, of which the following three compounds show the best binding afnity: Sorbitol, Mannitol and Galactitol. To understand the perfect binding orientation and the strength of non-bonded interactions, individual molecular docking studies were perform for the best hits. Further molecular dynamics studies were conduct to analyze the efcacy between the protein–ligand complexes and it was identify that Sorbitol obtains the highest efcacy. The best-screened compounds obtained drug-like property and were less toxic, which could be use as a potential lead compound to develop anti-Ebola drugs. -
Hemicellulose Arabinogalactan Hydrolytic Hydrogenation Over Ru-Modified H-USY Zeolites
Research Collection Journal Article Hemicellulose arabinogalactan hydrolytic hydrogenation over Ru-modified H-USY zeolites Author(s): Murzin, Dmitry; Kusema, Bright; Murzina, Elena V.; Aho, Atte; Tokarev, Anton; Boymirzaev, Azamat S.; Wärnå, Johan; Dapsens, Pierre Y.; Mondelli, Cecilia; Pérez-Ramírez, Javier; Salmi, Tapio Publication Date: 2015-10 Permanent Link: https://doi.org/10.3929/ethz-a-010792434 Originally published in: Journal of Catalysis 330, http://doi.org/10.1016/j.jcat.2015.06.022 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library Hemicellulose arabinogalactan hydrolytic hydrogenation over Ru-modified H-USY zeolites Dmitry Yu. Murzin1*, Bright Kusema2, Elena V. Murzina1, Atte Aho1, Anton Tokarev1, Azamat S. Boymirzaev3, Johan Wärnå1,4, Pierre Y. Dapsens2, Cecilia Mondelli2, Javier Pérez-Ramírez2, Tapio Salmi1 1Laboratory of Industrial Chemistry and Reaction Engineering, Process Chemistry Centre, Department of Chemical Engineering, Åbo Akademi University, FI-20500 Åbo/Turku, Finland, E-mail: [email protected] 2Institute for Chemical and Bioengineering, Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1, CH-8093 Zurich, Switzerland 3Namangan Institute of Engineering and Technology, Department of Chemical Technology, Namangan, 160115, Uzbekistan 4University of Umeå, Umeä, Sweden ABSTRACT The hydrolytic hydrogenation of hemicellulose arabinogalactan was investigated in the presence of protonic and Ru (1-5 wt.%)-modified USY zeolites (Si/Al ratio = 15 and 30). The use of the purely acidic materials was effective in depolymerizing the macromolecule into free sugars. While the latter partly dehydrated into 5- hydroxymethylfurfural and furfural, the generation of high molecular-weight compounds (aggregates of sugars and humins) was not favored, in contrast to previous evidences over beta zeolites. -
Sugar Alcohols a Sugar Alcohol Is a Kind of Alcohol Prepared from Sugars
Sweeteners, Good, Bad, or Something even Worse. (Part 8) These are Low calorie sweeteners - not non-calorie sweeteners Sugar Alcohols A sugar alcohol is a kind of alcohol prepared from sugars. These organic compounds are a class of polyols, also called polyhydric alcohol, polyalcohol, or glycitol. They are white, water-soluble solids that occur naturally and are used widely in the food industry as thickeners and sweeteners. In commercial foodstuffs, sugar alcohols are commonly used in place of table sugar (sucrose), often in combination with high intensity artificial sweeteners to counter the low sweetness of the sugar alcohols. Unlike sugars, sugar alcohols do not contribute to the formation of tooth cavities. Common Sugar Alcohols Arabitol, Erythritol, Ethylene glycol, Fucitol, Galactitol, Glycerol, Hydrogenated Starch – Hydrolysate (HSH), Iditol, Inositol, Isomalt, Lactitol, Maltitol, Maltotetraitol, Maltotriitol, Mannitol, Methanol, Polyglycitol, Polydextrose, Ribitol, Sorbitol, Threitol, Volemitol, Xylitol, Of these, xylitol is perhaps the most popular due to its similarity to sucrose in visual appearance and sweetness. Sugar alcohols do not contribute to tooth decay. However, consumption of sugar alcohols does affect blood sugar levels, although less than that of "regular" sugar (sucrose). Sugar alcohols may also cause bloating and diarrhea when consumed in excessive amounts. Erythritol Also labeled as: Sugar alcohol Zerose ZSweet Erythritol is a sugar alcohol (or polyol) that has been approved for use as a food additive in the United States and throughout much of the world. It was discovered in 1848 by British chemist John Stenhouse. It occurs naturally in some fruits and fermented foods. At the industrial level, it is produced from glucose by fermentation with a yeast, Moniliella pollinis. -
Oleaginous Yeasts for the Production of Sugar Alcohols Sujit S Jagtap1,2
Oleaginous Yeasts for the Production of Sugar Alcohols Sujit S Jagtap1,2* ([email protected]), Ashwini A Bedekar2, Jing-Jing Liu1, Anshu Deewan1,2, and Christopher V Rao1,2 1DOE Center for Advanced Bioenergy and Bioproducts Innovation, University of Illinois at Urbana-Champaign, Illinois. 2Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Illinois. https://cabbi.bio/ Project Goal: The goal of this project is to investigate sugar alcohol production from plant- based sugars and glycerol in the oleaginous yeasts Rhodosporidium toruloides and Yarrowia lipolytica. We are also interested in understanding the mechanism of sugar alcohol production and the key genes involved in the polyol synthesis process. Sugar alcohols are commonly used as low-calorie, natural sweeteners. They have also been proposed by the Department of Energy as potential building blocks for bio-based chemicals. They can be used to produce polymers with applications in medicine and as precursors to anti-cancer drugs 1. Production of these sugar alcohols by yeast often results, from redox imbalances associated with growth on different sugars, accumulation of toxic intermediates, and as a cell response to the high osmotic pressure of the environment 2-3. The ability of yeast to naturally produce these sugar alcohols from simple sugars provides a potentially safer and more sustainable alternative to traditional chemical hydrogenation. In our study, we found that the oleaginous yeast R. toruloides IFO0880 produces D-arabitol during growth on xylose in nitrogen-rich medium 3. Efficient xylose utilization was a prerequisite for extracellular D-arabitol production. D-arabitol is an overflow metabolite associated with transient redox imbalances during growth on xylose. -
Potentially Explosive Chemicals*
Potentially Explosive Chemicals* Chemical Name CAS # Not 1,1’-Diazoaminonaphthalene Assigned 1,1-Dinitroethane 000600-40-8 1,2,4-Butanetriol trinitrate 006659-60-5 1,2-Diazidoethane 000629-13-0 1,3,5-trimethyl-2,4,6-trinitrobenzene 000602-96-0 1,3-Diazopropane 005239-06-5 Not 1,3-Dinitro-4,5-dinitrosobenzene Assigned Not 1,3-dinitro-5,5-dimethyl hydantoin Assigned Not 1,4-Dinitro-1,1,4,4-tetramethylolbutanetetranitrate Assigned Not 1,7-Octadiene-3,5-Diyne-1,8-Dimethoxy-9-Octadecynoic acid Assigned 1,8 –dihydroxy 2,4,5,7-tetranitroanthraquinone 000517-92-0 Not 1,9-Dinitroxy pentamethylene-2,4,6,8-tetramine Assigned 1-Bromo-3-nitrobenzene 000585-79-5 Not 2,2',4,4',6,6'-Hexanitro-3,3'-dihydroxyazobenzene Assigned 2,2-di-(4,4,-di-tert-butylperoxycyclohexyl)propane 001705-60-8 2,2-Dinitrostilbene 006275-02-1 2,3,4,6- tetranitrophenol 000641-16-7 Not 2,3,4,6-tetranitrophenyl methyl nitramine Assigned Not 2,3,4,6-tetranitrophenyl nitramine Assigned Not 2,3,5,6- tetranitroso nitrobenzene Assigned Not 2,3,5,6- tetranitroso-1,4-dinitrobenzene Assigned 2,4,6-Trinitro-1,3,5-triazo benzene 029306-57-8 Not 2,4,6-trinitro-1,3-diazabenzene Assigned Not 2,4,6-Trinitrophenyl trimethylol methyl nitramine trinitrate Assigned Not 2,4,6-Trinitroso-3-methyl nitraminoanisole Assigned 2,4-Dinitro-1,3,5-trimethyl-benzene 000608-50-4 2,4-Dinitrophenylhydrazine 000119-26-6 2,4-Dinitroresorcinol 000519-44-8 2,5-dimethyl-2,5-diydroperoxy hexane 2-Nitro-2-methylpropanol nitrate 024884-69-3 3,5-Dinitrosalicylic acid 000609-99-4 Not 3-Azido-1,2-propylene glycol dinitrate -
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9 -
Cross-Coupling Reactions Using Samarium(II) Iodide Michal Szostak,* Neal J
Review pubs.acs.org/CR Cross-Coupling Reactions Using Samarium(II) Iodide Michal Szostak,* Neal J. Fazakerley, Dixit Parmar, and David J. Procter* School of Chemistry, University of Manchester, Oxford Road, Manchester, M13 9PL, United Kingdom 4.3. Aldol Reactions BM 5. Cross-Coupling As Part of Sequential and Cascade Reactions BM 5.1. Cascades Initiated by Radical Intermediates BN 5.2. Cascades Initiated by Anionic Intermediates BR 6. Conclusions BT Author Information BT Corresponding Authors BT Notes BT Biographies BT CONTENTS Acknowledgments BU 1. Introduction A References BU 2. Reactivity of Functional Groups toward Samarium Note Added in Proof CB Diiodide B 3. Cross-Coupling via Radical Intermediates C 3.1. Ketyl Radical-Alkene/Alkyne/Arene Cross- 1. INTRODUCTION Coupling C Since its introduction to organic synthesis in 1977 by Kagan,1,2 ’ 3.1.1. Intramolecular Cross-Coupling of Ketyl samarium(II) iodide (SmI2, Kagan s reagent) has gained the Radicals with Alkenes C status of one of the most versatile single-electron transfer − 3.1.2. Intermolecular Cross-Coupling of Ketyl reagents available in the laboratory.3 46 SmI occupies a unique − 2 Radicals with Alkenes S place among other reductants47 57 in that it is an extremely − 3.1.3. Cross-Coupling of Ketyl Radicals with powerful58 64 yet chemoselective reagent, whose selectivity Alkynes Y toward functional groups is fine-tuned by the use of appropriate 26−30 3.1.4. Cross-Coupling of Ketyl Radicals with ligands and additives. Transformations mediated by SmI2 Allenes Z are performed under user-friendly and operationally simple 3.1.5. -
Retinal Polyol and Myo-Lnosifol in Galactosemic Dogs Given an Aldose-Reducto.Se Inhibitor
Investigative Ophthalmology & Visual Science, Vol. 32, No. 13, December 1991 Copyright © Association for Research in Vision and Ophthalmology Retinal Polyol and Myo-lnosifol in Galactosemic Dogs Given an Aldose-Reducto.se Inhibitor Timothy 5. Kern and Ronald L. Engerman Galactitol and myo-\nosito\ concentrations were measured in retinas, erythrocytes, and skeletal muscle of experimentally galactosemic dogs receiving a placebo or the aldose reductase inhibitor, sorbinil, for 5 yr. The concentration of galactitol was increased more than 30-fold in the retina and other tissues by galactosemia, and the increase was inhibited 90-96% in all tissues by sorbinil. The concentration of free myo-inos\to\ was greater than normal in retinas of galactosemic dogs, and its concentration was not altered by the aldose-reductase inhibitor. The mjw-inositol concentration likewise was greater than normal in the retinas of dogs that were diabetic for 2-4 months. The marked inhibition of polyol production and accumulation in the retina of sorbinil-treated galactosemic dogs was not associated with a comparable inhibition of retinopathy. Invest Ophthalmol Vis Sci 32:3175-3177,1991 Experimental elevation of blood galactose concen- to receive either the aldose reductase inhibitor, sor- tration in normal dogs leads to a retinopathy that is binil, or to remain untreated. The dogs were fed twice morphologically similar to that in diabetic dogs and daily (8 AM and 6 PM) to maintain blood galactose humans.12 One mechanism by which hyperglycemia levels elevated as high as possible throughout the day. in diabetes or experimental galactosemia might cause Sorbinil was given orally twice a day, usually at a dose retinopathy is through excessive polyol production of 60-80 mg/kg/day, 30 min before each feeding. -
Prediction of the Crystalline Densities of Aliphatic Nitrates by Quantum Chemistry Methods
Central European Journal of Energetic Materials ISSN 1733-7178; e-ISSN 2353-1843 Copyright © 2019 Sieć Badawcza Łukasiewicz – Institute of Industrial Organic Chemistry, Poland Cent. Eur. J. Energ. Mater. 2019, 16(3): 412-432; DOI 10.22211/cejem/112306 Article is available in PDF-format, in colour, at: http://www.wydawnictwa.ipo.waw.pl/cejem/Vol-16-Number3-2019/CEJEM_00978.pdf Article is available under the Creative Commons Attribution-Noncommercial-NoDerivs 3.0 license CC BY-NC-ND 3.0. Research paper Prediction of the Crystalline Densities of Aliphatic Nitrates by Quantum Chemistry Methods Guixiang Wang,* Yimin Xu, Chuang Xue, Zhiyuan Ding, Yan Liu, Hui Liu, Xuedong Gong** Computation Institute for Molecules and Materials, Department of Chemistry, Nanjing University of Science and Technology, Nanjing 210094, China E-mails: * [email protected]; ** [email protected] Abstract: Crystal density is a basic and important parameter for predicting the detonation performance of explosives, and nitrate esters are a type of compound widely used in the military context. In this study, thirty-one aliphatic nitrates were investigated using the density functional theory method (B3LYP) in combination with six basis sets (3-21G, 6-31G, 6-31G*, 6-31G**, 6-311G* and 6-31+G**) and the semiempirical molecular orbital method (PM3). Based on the geometric optimizations at various theoretical levels, the molecular volumes and densities were calculated. Compared with the available experimental data, the densities calculated by various methods are all overestimated, and the errors of the PM3 and B3LYP/3-21G methods are larger than those of other methods. Considering the results and the computer resources required by the calculations, the B3LYP/6-31G* method is recommended for predicting the crystalline densities of organic nitrates using a fitting equation. -
Compositions Comprising Nebivolol
(19) TZZ ZZ__T (11) EP 2 808 015 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.12.2014 Bulletin 2014/49 A61K 31/34 (2006.01) A61K 31/502 (2006.01) A61K 31/353 (2006.01) A61P 9/00 (2006.01) (21) Application number: 14002458.9 (22) Date of filing: 16.11.2005 (84) Designated Contracting States: • O’Donnell, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Morgantown, WV 26505 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Bottini, Peter Bruce SK TR Morgantown, WV 26505 (US) • Mason, Preston (30) Priority: 31.05.2005 US 141235 Morgantown, WV 26504 (US) 10.11.2005 US 272562 • Shaw, Andrew Preston 15.11.2005 US 273992 Morgantown, WV 26504 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Samson & Partner accordance with Art. 76 EPC: Widenmayerstraße 5 09015249.7 / 2 174 658 80538 München (DE) 05848185.4 / 1 890 691 Remarks: (71) Applicant: MYLAN LABORATORIES, INC This application was filed on 16-07-2014 as a Morgantown, NV 26504 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: • Davis, Eric Morgantown, WV 26508 (US) (54) Compositions comprising nebivolol (57) The active ingredients of the pharmaceutical composition described consist of nebivolol, one or more ACE inhibitors and one or more ARB. EP 2 808 015 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 808 015 A1 Description [0001] This application is a continuation-in-part of application Ser. -
United States Patent (10) Patent No.: US 7,235,237 B2 L0scalz0 Et Al
USOO7235237B2 (12) United States Patent (10) Patent No.: US 7,235,237 B2 L0ScalZ0 et al. (45) Date of Patent: Jun. 26, 2007 (54) METHODS OF TREATING VASCULAR 5,968,983 A 10/1999 Kaesemeyer DISEASES CHARACTERIZED BY NITRC 5,973,011 A 10/1999 Noack et al. OXIDE INSUFFICIENCY 6,103,769 A 8, 2000 Kelm 6,117,872 A 9, 2000 Maxwell et al. (75) Inventors: Joseph Loscalzo, Dover, MA (US); 6,319,515 B1 1 1/2001 Hidaka et al. Joseph A. Vita, Hingham, MA (US); 6,458,797 B1 10/2002 Adams et al. Michael D. Loberg, Boston, MA (US); 2004, OO63719 A1 4/2004 Adams et al. Manuel Worcel, Boston, MA (US) FOREIGN PATENT DOCUMENTS (73) Assignee: NitroMed, Inc., Lexington, MA (US) EP O327263 A 8, 1989 (*) Notice: Subject to any disclaimer, the term of this EP O 968 713 A1 5, 1998 patent is extended or adjusted under 35 JP O905915.2 3, 1997 U.S.C. 154(b) by 492 days. WO WO95/26725 10, 1995 WO WO 98.21 193 5, 1998 (21) Appl. No.: 10/415,136 WO WO 99.00361 1, 1999 WO WO 99,66921 12/1999 (22) PCT Filed: May 2, 2001 WO WO 99,67231 12/1999 WO WO O1/35961 A 5, 2001 (86). PCT No.: PCT/USO1A14245 OTHER PUBLICATIONS S 371 (c)(1), (2), (4) Date: Apr. 25, 2003 Dupuis, Cardiovascular Drugs and Therapy, 8(3):501-507 (1994). Cohn et al. The New England Journal of Medicine, 325(5):303-310 (87) PCT Pub.